230 related articles for article (PubMed ID: 18328639)
1. Abuse liability assessment of atomoxetine in a drug-abusing population.
Jasinski DR; Faries DE; Moore RJ; Schuh LM; Allen AJ
Drug Alcohol Depend; 2008 May; 95(1-2):140-6. PubMed ID: 18328639
[TBL] [Abstract][Full Text] [Related]
2. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
Parasrampuria DA; Schoedel KA; Schuller R; Silber SA; Ciccone PE; Gu J; Sellers EM
J Clin Psychopharmacol; 2007 Oct; 27(5):459-67. PubMed ID: 17873677
[TBL] [Abstract][Full Text] [Related]
3. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
[TBL] [Abstract][Full Text] [Related]
4. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
[TBL] [Abstract][Full Text] [Related]
5. Discriminative-stimulus, self-reported, performance, and cardiovascular effects of atomoxetine in methylphenidate-trained humans.
Lile JA; Stoops WW; Durell TM; Glaser PE; Rush CR
Exp Clin Psychopharmacol; 2006 May; 14(2):136-47. PubMed ID: 16756417
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users.
Heil SH; Holmes HW; Bickel WK; Higgins ST; Badger GJ; Laws HF; Faries DE
Drug Alcohol Depend; 2002 Jul; 67(2):149-56. PubMed ID: 12095664
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.
Wilens TE; Adler LA; Weiss MD; Michelson D; Ramsey JL; Moore RJ; Renard D; Brady KT; Trzepacz PT; Schuh LM; Ahrbecker LM; Levine LR;
Drug Alcohol Depend; 2008 Jul; 96(1-2):145-54. PubMed ID: 18403134
[TBL] [Abstract][Full Text] [Related]
8. Effects of atomoxetine and methylphenidate on attention and impulsivity in the 5-choice serial reaction time test.
Navarra R; Graf R; Huang Y; Logue S; Comery T; Hughes Z; Day M
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Jan; 32(1):34-41. PubMed ID: 17714843
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine.
Wee S; Woolverton WL
Drug Alcohol Depend; 2004 Sep; 75(3):271-6. PubMed ID: 15283948
[TBL] [Abstract][Full Text] [Related]
10. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
Findling RL
Clin Ther; 2008 May; 30(5):942-57. PubMed ID: 18555941
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
Polzer J; Bangs ME; Zhang S; Dellva MA; Tauscher-Wisniewski S; Acharya N; Watson SB; Allen AJ; Wilens TE
Biol Psychiatry; 2007 Mar; 61(5):713-9. PubMed ID: 16996485
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys.
Gasior M; Bergman J; Kallman MJ; Paronis CA
Neuropsychopharmacology; 2005 Apr; 30(4):758-64. PubMed ID: 15526000
[TBL] [Abstract][Full Text] [Related]
13. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users.
Schoedel KA; Addy C; Chakraborty B; Rosko K; Dunbar S; Maes A; Chen N; Stoch SA; Wagner J; Chodakewitz J; Sellers EM
J Clin Psychopharmacol; 2012 Aug; 32(4):492-502. PubMed ID: 22722508
[TBL] [Abstract][Full Text] [Related]
14. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
15. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
Johnson MW; Suess PE; Griffiths RR
Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
[TBL] [Abstract][Full Text] [Related]
16. Effects of atomoxetine, desipramine, d-amphetamine and methylphenidate on impulsivity in juvenile rats, measured in a T-maze procedure.
Bizot JC; David S; Trovero F
Neurosci Lett; 2011 Feb; 489(1):20-4. PubMed ID: 21129437
[TBL] [Abstract][Full Text] [Related]
17. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
[TBL] [Abstract][Full Text] [Related]
18. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
[TBL] [Abstract][Full Text] [Related]
19. Absence of psychostimulant effects of a supratherapeutic dose of tianeptine: a placebo-controlled study versus methylphenidate in young healthy volunteers.
Bernard K; Penelaud PF; Mocaër E; Donazzolo Y
J Clin Psychopharmacol; 2011 Aug; 31(4):441-8. PubMed ID: 21694627
[TBL] [Abstract][Full Text] [Related]
20. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers.
Zacny JP
Psychopharmacology (Berl); 2003 Jan; 165(2):146-56. PubMed ID: 12404072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
